Endothelial dysfunction in chronic thromboembolic pulmonary hypertension: a comprehensive study of molecular, functional, and metabolic alterations
Text Complet
embargat.txt
Compartir
ENG- This thesis investigates the study of endothelial cells from patients with CTEPH to better understand how and why these cells lose their normal function, contributing to the maintenance of vascular obstruction and disease progression. Through the analysis of their structural, functional, genetic, and metabolic characteristics, this work aims to shed new light on the cellular mechanisms that differentiate CTEPH from other forms of pulmonary hypertension and to open new avenues towards more specific and effective treatments.
The study has uncovered various cellular and molecular mechanisms that help to better understand the pathology of CTEPH. It has been observed that endothelial cells from CTEPH patients present alterations in their internal structure—the cytoskeleton—which cause the loss of essential functions such as movement, repair, and response to blood flow. This dysfunction contributes to endothelial malfunction and disease progression. Moreover, it has been detected that this dysfunction affects not only the endothelial cells near the thrombotic tissue but also the circulating endothelial cells in the blood, indicating a systemic rather than only local alteration.
This dysfunction has also been studied at the genetic and metabolomic levels, revealing that endothelial cells from CTEPH patients show changes compared to cells from healthy individuals. Particularly notable are alterations in ribosomes (involved in protein production) and mitochondria (the cell’s energy producers), suggesting a profound disruption of cellular function. Likewise, metabolomic analysis reveals significant differences in CTEPH patients, with observed lipid imbalances and reduced fat metabolism. These alterations could help in identifying the disease and guiding future treatments.
These findings allow differentiation of CTEPH from other forms of pulmonary hypertension and offer clues to develop more precise diagnostics and targeted therapies that address endothelial dysfunction at its origin
ADVERTIMENT. Tots els drets reservats. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs.
DUGiDocs